drugset / Trial / NCT06109649

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

NCT06109649 ↗

Phase 3 Active not recruiting 200 enrolled Clinuvel, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.

Timeline

Start
2023-10-11
Primary completion
2025-12
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Afamelanotide Peptide — —

Indications